Liquidia Technologies LQDA 深 滬
已收盤 12-24 16:00:00 美东时间
35.79
+0.550
+1.56%
華盛通- 最 高36.41
- 今 開35.41
- 成交量 40.95万股
- 最 低 35.13
- 昨 收 35.24
- 總市值 31.14亿
- 52周最高 36.41
- 市盈率 靜 --
- 換手率 0.47%
- 52周最低 11.26
- 委 比 81.38%
- 總股本 8699.55万
- 歷史最高 38.46
- 量 比 0.40
- 振 幅 3.63%
- 歷史最低 2.25
- 每 手 1
- 風險率 6.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Liquidia’s Phase 3 Study: Pioneering Treatment for Pulmonary Hypertension
Liquidia Technologies ($LQDA) announced an update on their ongoing clinical stu...
12-18 00:32
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Nasdaq Composite falling more than 350 points ...
11-05 01:37
BTIG Reiterates Buy on Liquidia, Maintains $49 Price Target
BTIG analyst Julian Harrison reiterates Liquidia (NASDAQ:LQDA) with a Buy and maintains $49 price target.
11-04 18:32
Liquidia Q3 EPS $(0.04) Beats $(0.40) Estimate, Sales $54.342M Beat $18.825M Estimate
Liquidia (NASDAQ:LQDA) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.40) by 90.02 percent. This is a 89.74 percent increase over losses of $(0.39) per share from the same
11-03 19:31
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
Liquidia Corporation announced that its executive leadership team will provide updates during fireside chats at two investor conferences in November: the 2025 UBS Global Healthcare Conference on November 10 and the Jefferies London Healthcare Conference on November 18. Webcasts of both presentations will be available on Liquidia’s website, with archived versions accessible for 30 days post-event. Liquidia, a biopharmaceutical company, revolutioni...
11-03 13:00
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Liquidia Corporation reported third-quarter 2025 financial results, highlighting $51.7 million in net product sales of YUTREPIA™, achieving profitability in its first full quarter of sales. The company saw over 2,000 unique patient prescriptions and 1,500 patient starts. Financials showed a net loss of $3.5 million, improved profitability with $1.7 million in operating income, and $157.5 million in cash equivalents.YUTREPIA's strong launch and gr...
11-03 11:30
What's Next: Liquidia's Earnings Preview
Liquidia (NASDAQ:LQDA) is set to give its latest quarterly earnings report on M...
11-01 00:03
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
